Loading…
Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response
Loss of HLA class I expression on tumor cells is a frequent event as an immune escape mechanism. Seven different altered HLA phenotypes have been defined in tumors. Various molecular mechanisms have been described as responsible for HLA class I loss. HLA class I expression alterations occur successi...
Saved in:
Published in: | International journal of cancer 2007-11, Vol.121 (9), p.2023-2030 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4195-581c97746adcbe7f133fb62cefdcaa37c2d2e21105cbfba9026cd098f160e5cc3 |
---|---|
cites | cdi_FETCH-LOGICAL-c4195-581c97746adcbe7f133fb62cefdcaa37c2d2e21105cbfba9026cd098f160e5cc3 |
container_end_page | 2030 |
container_issue | 9 |
container_start_page | 2023 |
container_title | International journal of cancer |
container_volume | 121 |
creator | Paco, Laura Garcia‐Lora, Angel Miguel Casares, Carlos Cabrera, Carmen Algarra, Ignacio Collado, Antonia Maleno, Isabel Garrido, Federico Lopez‐Nevot, Miguel Angel |
description | Loss of HLA class I expression on tumor cells is a frequent event as an immune escape mechanism. Seven different altered HLA phenotypes have been defined in tumors. Various molecular mechanisms have been described as responsible for HLA class I loss. HLA class I expression alterations occur successively and unpredictably during tumor progression in vivo and immunoselection has been implicated in this process. We present an experimental xenograft model in which melanoma cell line Ando‐2 injected into athymic nude mice lost total surface HLA class I expression and exhibited HLA class II cell surface expression. A strong down‐regulation of HLA class I expression and de novo HLA class II expression were also found when Ando‐2 melanoma cells were injected into SCID‐Beige mice. These phenomena were reproducible and were only observed in local growth in nude or SCID‐Beige mice and not in vitro after multiple passages. HLA class I surface expression was recovered after IFN‐γ treatment, indicating regulatory defects. The mechanism implicated in loss of HLA class I molecule expression were a down‐regulation of different components of antigen processing machinery and HLA class I heavy chains. These data suggest that HLA class I alterations can also occur in absence of autologous adaptive immune response. This is a good experimental in vivo model to study the relationship between tumor progression and HLA class I alterations. © 2007 Wiley‐Liss, Inc. |
doi_str_mv | 10.1002/ijc.22925 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68298971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20571056</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4195-581c97746adcbe7f133fb62cefdcaa37c2d2e21105cbfba9026cd098f160e5cc3</originalsourceid><addsrcrecordid>eNqFkd9qFDEUxoModq1e-AKSG4VeTJtkNpnJZVnUrix4U6-HM5mTmpI_azJD7SP0rc26C70SIZAc8sv3nZyPkPecXXLGxJW7N5dCaCFfkBVnumuY4PIlWdU71nS8VWfkTSn3jHEu2fo1OeOdElyJfkWebtMMnvpUCk2W3uyuqfFQiy3F3_uMpbgUaV1AA3qIKQA16OsLF5GCnTHTu5we5p_URRqXCWlwBg8FjAVjPVZZWObk011aCoU4u3kJKVMXwlI1qsc-xYJvySsLvuC7035Ofnz5fLu5aXbfv24317vGrLmWjey50V23VjCZETvL29aOShi0kwFoOyMmgYJzJs1oR9BMKDMx3VuuGEpj2nPy6ai7z-nXgmUegiuHL0HE2uCgeqF7Xaf2P1Aw2VUbVcGLI2hyHWNGO-yzC5AfB86GQ0BDDWj4G1BlP5xElzHg9EyeEqnAxxMAxYC3GaJx5ZnTTLFeHrirI_fgPD7-23HYftscrf8AXV6o4Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20571056</pqid></control><display><type>article</type><title>Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Paco, Laura ; Garcia‐Lora, Angel Miguel ; Casares, Carlos ; Cabrera, Carmen ; Algarra, Ignacio ; Collado, Antonia ; Maleno, Isabel ; Garrido, Federico ; Lopez‐Nevot, Miguel Angel</creator><creatorcontrib>Paco, Laura ; Garcia‐Lora, Angel Miguel ; Casares, Carlos ; Cabrera, Carmen ; Algarra, Ignacio ; Collado, Antonia ; Maleno, Isabel ; Garrido, Federico ; Lopez‐Nevot, Miguel Angel</creatorcontrib><description>Loss of HLA class I expression on tumor cells is a frequent event as an immune escape mechanism. Seven different altered HLA phenotypes have been defined in tumors. Various molecular mechanisms have been described as responsible for HLA class I loss. HLA class I expression alterations occur successively and unpredictably during tumor progression in vivo and immunoselection has been implicated in this process. We present an experimental xenograft model in which melanoma cell line Ando‐2 injected into athymic nude mice lost total surface HLA class I expression and exhibited HLA class II cell surface expression. A strong down‐regulation of HLA class I expression and de novo HLA class II expression were also found when Ando‐2 melanoma cells were injected into SCID‐Beige mice. These phenomena were reproducible and were only observed in local growth in nude or SCID‐Beige mice and not in vitro after multiple passages. HLA class I surface expression was recovered after IFN‐γ treatment, indicating regulatory defects. The mechanism implicated in loss of HLA class I molecule expression were a down‐regulation of different components of antigen processing machinery and HLA class I heavy chains. These data suggest that HLA class I alterations can also occur in absence of autologous adaptive immune response. This is a good experimental in vivo model to study the relationship between tumor progression and HLA class I alterations. © 2007 Wiley‐Liss, Inc.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.22925</identifier><identifier>PMID: 17621628</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Animals ; APM down‐regulation ; autologous immune response ; Biological and medical sciences ; Cell Line, Tumor ; Cell Membrane - metabolism ; Dermatology ; Disease Progression ; Down-Regulation ; Gene Expression Regulation, Neoplastic ; Genome - genetics ; Histocompatibility Antigens Class I - genetics ; Histocompatibility Antigens Class I - immunology ; Histocompatibility Antigens Class I - metabolism ; Histocompatibility Antigens Class II - genetics ; Histocompatibility Antigens Class II - immunology ; Histocompatibility Antigens Class II - metabolism ; HLA alterations ; Medical sciences ; Melanoma - genetics ; Melanoma - immunology ; Melanoma - metabolism ; Melanoma - pathology ; Mice ; Mice, Nude ; Neoplasm Transplantation ; nude mice ; RNA, Messenger - genetics ; tumor cell ; Tumors ; Tumors of the skin and soft tissue. Premalignant lesions ; Xenograft model</subject><ispartof>International journal of cancer, 2007-11, Vol.121 (9), p.2023-2030</ispartof><rights>Copyright © 2007 Wiley‐Liss, Inc.</rights><rights>2007 INIST-CNRS</rights><rights>Copyright (c) 2007 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4195-581c97746adcbe7f133fb62cefdcaa37c2d2e21105cbfba9026cd098f160e5cc3</citedby><cites>FETCH-LOGICAL-c4195-581c97746adcbe7f133fb62cefdcaa37c2d2e21105cbfba9026cd098f160e5cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19060858$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17621628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paco, Laura</creatorcontrib><creatorcontrib>Garcia‐Lora, Angel Miguel</creatorcontrib><creatorcontrib>Casares, Carlos</creatorcontrib><creatorcontrib>Cabrera, Carmen</creatorcontrib><creatorcontrib>Algarra, Ignacio</creatorcontrib><creatorcontrib>Collado, Antonia</creatorcontrib><creatorcontrib>Maleno, Isabel</creatorcontrib><creatorcontrib>Garrido, Federico</creatorcontrib><creatorcontrib>Lopez‐Nevot, Miguel Angel</creatorcontrib><title>Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Loss of HLA class I expression on tumor cells is a frequent event as an immune escape mechanism. Seven different altered HLA phenotypes have been defined in tumors. Various molecular mechanisms have been described as responsible for HLA class I loss. HLA class I expression alterations occur successively and unpredictably during tumor progression in vivo and immunoselection has been implicated in this process. We present an experimental xenograft model in which melanoma cell line Ando‐2 injected into athymic nude mice lost total surface HLA class I expression and exhibited HLA class II cell surface expression. A strong down‐regulation of HLA class I expression and de novo HLA class II expression were also found when Ando‐2 melanoma cells were injected into SCID‐Beige mice. These phenomena were reproducible and were only observed in local growth in nude or SCID‐Beige mice and not in vitro after multiple passages. HLA class I surface expression was recovered after IFN‐γ treatment, indicating regulatory defects. The mechanism implicated in loss of HLA class I molecule expression were a down‐regulation of different components of antigen processing machinery and HLA class I heavy chains. These data suggest that HLA class I alterations can also occur in absence of autologous adaptive immune response. This is a good experimental in vivo model to study the relationship between tumor progression and HLA class I alterations. © 2007 Wiley‐Liss, Inc.</description><subject>Animals</subject><subject>APM down‐regulation</subject><subject>autologous immune response</subject><subject>Biological and medical sciences</subject><subject>Cell Line, Tumor</subject><subject>Cell Membrane - metabolism</subject><subject>Dermatology</subject><subject>Disease Progression</subject><subject>Down-Regulation</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genome - genetics</subject><subject>Histocompatibility Antigens Class I - genetics</subject><subject>Histocompatibility Antigens Class I - immunology</subject><subject>Histocompatibility Antigens Class I - metabolism</subject><subject>Histocompatibility Antigens Class II - genetics</subject><subject>Histocompatibility Antigens Class II - immunology</subject><subject>Histocompatibility Antigens Class II - metabolism</subject><subject>HLA alterations</subject><subject>Medical sciences</subject><subject>Melanoma - genetics</subject><subject>Melanoma - immunology</subject><subject>Melanoma - metabolism</subject><subject>Melanoma - pathology</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Neoplasm Transplantation</subject><subject>nude mice</subject><subject>RNA, Messenger - genetics</subject><subject>tumor cell</subject><subject>Tumors</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><subject>Xenograft model</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqFkd9qFDEUxoModq1e-AKSG4VeTJtkNpnJZVnUrix4U6-HM5mTmpI_azJD7SP0rc26C70SIZAc8sv3nZyPkPecXXLGxJW7N5dCaCFfkBVnumuY4PIlWdU71nS8VWfkTSn3jHEu2fo1OeOdElyJfkWebtMMnvpUCk2W3uyuqfFQiy3F3_uMpbgUaV1AA3qIKQA16OsLF5GCnTHTu5we5p_URRqXCWlwBg8FjAVjPVZZWObk011aCoU4u3kJKVMXwlI1qsc-xYJvySsLvuC7035Ofnz5fLu5aXbfv24317vGrLmWjey50V23VjCZETvL29aOShi0kwFoOyMmgYJzJs1oR9BMKDMx3VuuGEpj2nPy6ai7z-nXgmUegiuHL0HE2uCgeqF7Xaf2P1Aw2VUbVcGLI2hyHWNGO-yzC5AfB86GQ0BDDWj4G1BlP5xElzHg9EyeEqnAxxMAxYC3GaJx5ZnTTLFeHrirI_fgPD7-23HYftscrf8AXV6o4Q</recordid><startdate>20071101</startdate><enddate>20071101</enddate><creator>Paco, Laura</creator><creator>Garcia‐Lora, Angel Miguel</creator><creator>Casares, Carlos</creator><creator>Cabrera, Carmen</creator><creator>Algarra, Ignacio</creator><creator>Collado, Antonia</creator><creator>Maleno, Isabel</creator><creator>Garrido, Federico</creator><creator>Lopez‐Nevot, Miguel Angel</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20071101</creationdate><title>Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response</title><author>Paco, Laura ; Garcia‐Lora, Angel Miguel ; Casares, Carlos ; Cabrera, Carmen ; Algarra, Ignacio ; Collado, Antonia ; Maleno, Isabel ; Garrido, Federico ; Lopez‐Nevot, Miguel Angel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4195-581c97746adcbe7f133fb62cefdcaa37c2d2e21105cbfba9026cd098f160e5cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>APM down‐regulation</topic><topic>autologous immune response</topic><topic>Biological and medical sciences</topic><topic>Cell Line, Tumor</topic><topic>Cell Membrane - metabolism</topic><topic>Dermatology</topic><topic>Disease Progression</topic><topic>Down-Regulation</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genome - genetics</topic><topic>Histocompatibility Antigens Class I - genetics</topic><topic>Histocompatibility Antigens Class I - immunology</topic><topic>Histocompatibility Antigens Class I - metabolism</topic><topic>Histocompatibility Antigens Class II - genetics</topic><topic>Histocompatibility Antigens Class II - immunology</topic><topic>Histocompatibility Antigens Class II - metabolism</topic><topic>HLA alterations</topic><topic>Medical sciences</topic><topic>Melanoma - genetics</topic><topic>Melanoma - immunology</topic><topic>Melanoma - metabolism</topic><topic>Melanoma - pathology</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Neoplasm Transplantation</topic><topic>nude mice</topic><topic>RNA, Messenger - genetics</topic><topic>tumor cell</topic><topic>Tumors</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><topic>Xenograft model</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paco, Laura</creatorcontrib><creatorcontrib>Garcia‐Lora, Angel Miguel</creatorcontrib><creatorcontrib>Casares, Carlos</creatorcontrib><creatorcontrib>Cabrera, Carmen</creatorcontrib><creatorcontrib>Algarra, Ignacio</creatorcontrib><creatorcontrib>Collado, Antonia</creatorcontrib><creatorcontrib>Maleno, Isabel</creatorcontrib><creatorcontrib>Garrido, Federico</creatorcontrib><creatorcontrib>Lopez‐Nevot, Miguel Angel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paco, Laura</au><au>Garcia‐Lora, Angel Miguel</au><au>Casares, Carlos</au><au>Cabrera, Carmen</au><au>Algarra, Ignacio</au><au>Collado, Antonia</au><au>Maleno, Isabel</au><au>Garrido, Federico</au><au>Lopez‐Nevot, Miguel Angel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2007-11-01</date><risdate>2007</risdate><volume>121</volume><issue>9</issue><spage>2023</spage><epage>2030</epage><pages>2023-2030</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>Loss of HLA class I expression on tumor cells is a frequent event as an immune escape mechanism. Seven different altered HLA phenotypes have been defined in tumors. Various molecular mechanisms have been described as responsible for HLA class I loss. HLA class I expression alterations occur successively and unpredictably during tumor progression in vivo and immunoselection has been implicated in this process. We present an experimental xenograft model in which melanoma cell line Ando‐2 injected into athymic nude mice lost total surface HLA class I expression and exhibited HLA class II cell surface expression. A strong down‐regulation of HLA class I expression and de novo HLA class II expression were also found when Ando‐2 melanoma cells were injected into SCID‐Beige mice. These phenomena were reproducible and were only observed in local growth in nude or SCID‐Beige mice and not in vitro after multiple passages. HLA class I surface expression was recovered after IFN‐γ treatment, indicating regulatory defects. The mechanism implicated in loss of HLA class I molecule expression were a down‐regulation of different components of antigen processing machinery and HLA class I heavy chains. These data suggest that HLA class I alterations can also occur in absence of autologous adaptive immune response. This is a good experimental in vivo model to study the relationship between tumor progression and HLA class I alterations. © 2007 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17621628</pmid><doi>10.1002/ijc.22925</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0020-7136 |
ispartof | International journal of cancer, 2007-11, Vol.121 (9), p.2023-2030 |
issn | 0020-7136 1097-0215 |
language | eng |
recordid | cdi_proquest_miscellaneous_68298971 |
source | Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list) |
subjects | Animals APM down‐regulation autologous immune response Biological and medical sciences Cell Line, Tumor Cell Membrane - metabolism Dermatology Disease Progression Down-Regulation Gene Expression Regulation, Neoplastic Genome - genetics Histocompatibility Antigens Class I - genetics Histocompatibility Antigens Class I - immunology Histocompatibility Antigens Class I - metabolism Histocompatibility Antigens Class II - genetics Histocompatibility Antigens Class II - immunology Histocompatibility Antigens Class II - metabolism HLA alterations Medical sciences Melanoma - genetics Melanoma - immunology Melanoma - metabolism Melanoma - pathology Mice Mice, Nude Neoplasm Transplantation nude mice RNA, Messenger - genetics tumor cell Tumors Tumors of the skin and soft tissue. Premalignant lesions Xenograft model |
title | Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T15%3A14%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Total%20loss%20of%20HLA%20class%20I%20expression%20on%20a%20melanoma%20cell%20line%20after%20growth%20in%20nude%20mice%20in%20absence%20of%20autologous%20antitumor%20immune%20response&rft.jtitle=International%20journal%20of%20cancer&rft.au=Paco,%20Laura&rft.date=2007-11-01&rft.volume=121&rft.issue=9&rft.spage=2023&rft.epage=2030&rft.pages=2023-2030&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/ijc.22925&rft_dat=%3Cproquest_cross%3E20571056%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4195-581c97746adcbe7f133fb62cefdcaa37c2d2e21105cbfba9026cd098f160e5cc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20571056&rft_id=info:pmid/17621628&rfr_iscdi=true |